8:30 PM
 | 
Jan 26, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Metadoxine ER: Ph III MEASURE data

Top-line data from the double-blind, U.S. and Israeli Phase III MEASURE trial in 283 adult patients with ADHD showed that once-daily 1,400 mg oral metadoxine ER missed the primary endpoint of improving CAARS from baseline...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >